The clinical relevance of transforming growth factor-beta (TGF-b)-signalling pathway in breast carcinomas (BCs) remained elusive. This study aimed to evaluate the prognostic value of TGF-b1 and transforming growth factor-beta type II receptor (TGF-bRII) expression levels in tumour cells and their association with the established biomarkers in BC.
mutation and/or functional inactivation of TGF-b receptors or by downstream alterations in the Smad-signalling pathway. Decreased expression of TGF-b receptors, including TGF-bRII, has been proposed as a mechanism in BC to evade the TGFb-mediated growth inhibition [2, 3] . Loss of TGF-bRII protein expression in epithelial cells in typical breast hyperplasia was associated with increased risk of subsequent invasive cancer [4] .
Data from experimental models have shown that in the later stages of carcinogenesis, TGF-b induces an invasive and prometastatic phenotype in cancer cells characterised by an epithelial-to-mesenchymal transition [3, 5] . This opposite role of TGF-b in breast carcinogenesis could be partly explained by the cross talk between steroid hormone receptor signal transduction and the TGF-b system in hormone-responsive tissues [2] . In addition, TGF-b can modify tumoral risk and aggressiveness initiated by different oncogenes, such as the HER2 oncogene. Transgenic animal models and in vitro assays in BC cell lines showed that HER2 amplification inhibits the antiproliferative actions of TGF-b1 [6, 7] . However, to the best of our knowledge, no studies have addressed the association between TGF-b and HER2 and clinical outcome in human BC.
Studies evaluating the prognostic role of TGF-b1 in human BC cells reported conflicting results. TGFB1 messenger RNA (mRNA) overexpression in BC was significantly associated with favourable outcome [8] . Down-expression of TGF-b1 protein was also related to recurrence in early-stage breast tumours [9] . In contrast, other studies have shown that TGF-b1 protein overexpression was related to worse outcome [10, 11] .
To clarify the relevance of TGF-b1 and TGF-bRII as prognostic markers in human BCs, mRNA and protein levels were assessed by quantitative RT-PCR and immunohistochemistry and compared with the usual histological and clinical parameters.
materials and methods tissue samples and patients' characteristics
Breast tumour samples (N = 324) were obtained from the Amaral Carvalho Hospital (Jaú , São Paulo, Brazil) and from the A.C. Camargo Cancer Hospital (São Paulo, Brazil).
The mRNA analysis was carried out on 49 fresh tumour tissues. Protein analysis included 43 formalin fixed paraffin-embedded (FFPE) tumour tissue blocks in conventional slides and 275 invasive carcinomas arranged in tissue microarray (TMA). In 31 of 43 tumours (conventional slides), the adjacent normal breast tissues were also evaluated. Five normal fresh breast tissues and two paired FFPE breast tissue blocks were obtained from patients who had undergone mammary reduction and were considered as controls. Supplemental Table 1 (available at Annals of Oncology online) summarises the clinical and histopathological features of the BC patients.
Patients were followed prospectively with a mean follow-up of 68.8 6 42.8 months (2-178 months). All samples were from untreated patients before surgery. Sixty-four of 314 patients received neoadjuvant chemotherapy and 8 received neoadjuvant radiotherapy. Surgery was the primary treatment in 232 patients. A total of 154 patients received chemotherapy, 137 hormonal and 231 radiation adjuvant therapies. Two patients with clinical stage IIIB were treated with neoadjuvant chemotherapy and sequential radiotherapy without surgical treatment and one patient with stage IIIB was exclusively submitted to radiotherapy. All patients were advised of the procedures and provided written informed consent approved by the Institution's Ethics Committee.
quantitative RT-PCR
Fresh tumour and normal breast tissues were microdissected and total RNA was extracted using the RNeasy Mini Kit (Qiagen GmbH; Hilden, Germany) according to the manufacturer's recommendations. RNA extraction and complementary DNA (cDNA) synthesis were carried out as described [12] .
Relative expression of ESR1, PGR and HER2 in tumour and control samples was detected as previously described [12, 13] . Primer set sequences were as follows: for TGFB1, (F)-5#-GGCTACCATGCCAACTTCT-3# and (R)-5#-TGTACAACCAGCATAACCCGG-3#; for TGFBR2, (F)-5#-TGGGAAATGACATCTCGCTG-3# and (R)-5#-CCCTGTGTCGAAAG-CATGAA-3# and for GAPDH, (F)-5#-GGCCTCCAAGGAGTAAGACC-3# and (R)-5#-AGGGGTCTACATGGCAACTG-3#. The PCR was conducted in a total volume of 10 ll containing Power SYBRÒ Green PCR Master Mix (Applied Biosystems; Foster City, CA), 1 ll cDNA (1 : 10) and 200 nM of each primer. The reactions were carried out in an ABI Prism 7000 Sequence Detection System (Applied Biosystems). Dissociation and standard curves for all primers were constructed. PCR efficiency (E) was calculated according to the equation: E = 10 (21/slope) 21 . Gene relative quantification (RQ) was calculated according to Pfaffl [14] . The transcript levels were considered up-regulated (RQ ‡ 2.0) or down-regulated (RQ £ 0.5).
immunohistochemistry analysis
TMA was constructed as previously described [15] . TMA and FFPE tissues from 43 BC and 2 normal breast samples were freshly cut (3 lm) and the sections were mounted on conventional slides with organosilane (3-aminopropyltriethoxysilane) (Sigma-Aldrich Co.; St Louis, MO). Immunohistochemical reactions were carried out using the polyclonal rabbit antibody anti-TGF-b1 RB-10347-P (Lab Vision; Fremont, CA) (dilution 1 : 125) and polyclonal rabbit antibody anti-TGF-bRII RB-10345-P (Lab Vision) (dilution 1 : 125). After 60 min of incubation, the sections were washed in phosphate-buffered saline (PBS), incubated for 30 min with secondary biotinylated antibody, followed by incubation with streptavidin-peroxidase complex (LSAB; DAKO, Carpinteria, CA) for 30 min. The sections were developed with 3,3#-diaminobenzidine and counterstained with hematoxylin-eosin.
Normal placental tissue was used as a positive control in each assay to quantify the TGF-b1 and TGF-bRII expression levels. TGF-b1 and TGFbRII were assessed by two negative controls (omitting the primary antibody and incubating slides with PBS and replacing the primary antibody with normal rabbit serum). The final scores were obtained according to immunostaining intensity in epithelial cells and were designated as negative (score 0) or positive (score 1-3). The analysis was carried out by two observers (MACD and FAS) and the samples were scored blinded with respect to clinical patient data. In case of discrepant recording, a consensus score was used.
statistical analysis
Kruskal-Wallis or Mann-Whitney test was applied to compare TGFB1 and TGFBR2 transcript levels and clinicopathological characteristics. HER2 status was considered as positive (score 3+) and negative (score 0-1+); scores 2+ were excluded from the analyses. Correlation analyses for gene expression were carried out using Spearman's rank test. The chi-square test was applied to determine the strength of association between the categorical variables.
Disease-free survival (DFS) and overall survival (OS) probabilities were calculated using the Kaplan-Meier method. The end point for OS analysis was restricted to death due to breast cancer and for DFS analysis, the end point was distant metastasis diagnosis. Stage IV patients were excluded from these analyses. Kaplan-Meier survival curves for TGF-b and TGF-bRII were also calculated in BC patients stratified according to ER, PgR and HER2 status. Multivariate analysis was carried out using Cox proportional hazards results
TGF-b1 and TGF-bRII expression in breast tumours and clinical-histopathological variables
Lower TGFBR2 mRNA levels were detected in breast tumours compared with normal breast tissues (P = 0.012), but no difference was observed for TGFB1 transcripts ( Figure 1A) . A positive correlation between TGFB1 and TGFBR2 levels was found in breast tumour samples (r = 0.72, P < 0.0001, data not shown).
TGF-b1 and TGF-bRII protein analyses exhibited predominantly cytoplasmic and membranous immunostaining, respectively ( Figure 1B-D) . TGF-b1-negative immunostaining was more frequently detected in tumours than in normal adjacent breast tissues (P < 0.0001; supplemental Table 2 , available at Annals of Oncology online). In agreement with the mRNA results, tumour samples showed significant TGF-bRII protein down-expression (P < 0.0001; supplemental Table 2 , available at Annals of Oncology online). A positive association was observed between TGF-b1 and TGF-bRII protein expressions (P < 0.0001, data not shown).
A significant correlation between TGF-b1 and TGF-bRII expression levels was determined in the transcript and protein analyses. Paired mRNA and protein samples showed a 74% concordance rate for TGF-b1 expression levels and 95% considering stromal cells (data not shown).
Negative association between TGF-bRII and ER protein status (P = 0.035) and a marginally significant association between TGF-b1 and PgR (P = 0.048) were detected ( Table 1) .
TGF-b1 and HER2 levels were marginally associated, both in transcript (n = 40, r = 0.29, P = 0.062, data not shown) and original article Annals of Oncology protein analyses (P = 0.047). TGFBR2 and HER2 mRNA expression levels showed significant correlation in the tumour tissues (n = 40, r = 0.43, P = 0.006; data not shown), which was confirmed in protein analysis (P < 0.001; Table 1 ). A significant association was found between TGF-bRIInegative tumours and distant metastasis at diagnosis (P = 0.027). Moreover, TGF-b1-and TGF-bRII-negative tumours were significantly associated with distant metastasis detected during the follow-up period (P = 0.003 and P = 0.029, respectively) ( Table 1) .
TGF-b1 and TGF-bRII protein expression as prognostic markers in breast tumours TGF-b1-positive tumours were associated with increased DFS in BC patients (n = 291, P = 0.023; supplemental Table 3 , available at Annals of Oncology online). A marginally significant association was observed between TGF-bRII status and DFS (P = 0.059). No association was observed between TGF-b1 and TGF-bRII and OS (supplemental Table 3 , available at Annals of Oncology online). As expected, significant associations were detected between the clinical outcome and the established prognostic factors (nodal status, clinical stage, tumour grade and ER and PgR status). Multivariate analysis revealed that TGF-b1 protein status is an independent prognostic factor for DFS. TGF-b1-positive tumours showed lower risk of metastasis [n = 243, hazard ratio (HR) = 0.489, P = 0.003; supplemental Table 4 , available at Annals of Oncology online).
BC patients were stratified according to receptors status (ER, PgR and HER2) and Kaplan-Meier survival curves were calculated. No statistical difference was observed between the survival curves for TGF-b1 or TGF-bRII status grouped according to ER or PgR status or in HER2-positive subgroup (data not shown). However, in HER2-negative group (n = 216), TGF-b1-and TGF-bRII-positive tumours showed significantly increased DFS (P = 0.013 and P = 0.002, respectively; Figure 2 and Table 2 ). The impact of TGF-bRII status on OS was markedly different in the HER2-negative group (P = 0.005). The established prognostic factors (nodal status, tumour grade, clinical stage and ER status) were also significantly associated with DFS and OS in these patients ( Table 2) .
Multivariate analysis on the HER2-negative cases (n = 179) demonstrated that TGF-bRII status is an independent prognostic factor for DFS and OS (Table 3 ). Lower risk of metastasis and death due to the disease were observed in TGFbRII-positive tumour patients (HR = 0.439, P = 0.001 and HR = 0.409, P = 0.003, respectively). Furthermore, in the HER2-negative group, ER status, clinical stage and nodal status were also detected as independent prognostic factors for DFS and OS (Table 3) .
Survival analysis in triple-negative (ER2/PgR2/HER22) patients (n = 54) showed increased DFS in TGF-b1-and TGF-bRII-positive patients (P = 0.035 and P = 0.013, respectively; data not shown). TGF-bRII-negative expression, Figure 2 . Disease-free survival and overall survival curves according to transforming growth factor-beta-1 (TGF-b1) (A and B) and transforming growth factor-beta type II receptor (TGF-bRII) (C and D) protein expression in human epidermal growth factor receptor-2-negative breast cancer patients. P values were determined by log-rank test.
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but not TGF-b1, was significantly associated with decreased OS (P = 0.034 and P = 0.062, respectively; data not shown).
discussion
Growing evidence supports that the regulatory role of TGF-b in the tumour microenvironment is cell type and context dependant [3, 16] . However, the clinical relevance of TGF-b signalling in breast cancer cells remains uncertain.
Down-regulation of TGF-b1 protein expression in tumour cells compared with normal breast tissues was detected. In addition, breast tumours presented significant low expression of TGF-bRII, both in transcript and protein levels. Previous study also reported negative TGF-b1 immunostaining in 49% of invasive carcinomas (n = 61) [9] . Down-expression of TGFbRII in breast tumours in transcript [17] and protein levels [18] has also been described. TGF-b tumour suppressor activity comprises direct growth-inhibitory effects in target cells and blockage of the growth factors production by stromal fibroblasts and inflammatory cells, which could favour tumour progression [3, 18] . Down-regulation of TGF-b receptors is one of the proposed mechanisms evolved by malignant cells to bypass the suppressive effects of TGF-b [3, 16] . Taken together, these data indicate that the down-regulation of TGF-b1 and TGF-bRII are important events in breast carcinogenesis.
TGF-b1-and TGF-bRII-negative tumours were significantly associated with metastasis occurrence. Additionally, survival analysis showed that TGF-b1 protein expression in tumour cells is an independent prognostic marker for DFS in BC patients. No association between TGF-b1 and TGF-bRII protein status and the site of metastasis occurrence was detected (data not shown). In agreement with our data, previous study showed that TGF-b1-positive tumours were significantly associated with good prognosis [19] . Loss of TGFb1 protein expression was also associated with worse outcome in patients with T1-2N0 breast tumours [9] . In contrast, intense immunoreactivity of TGF-b1 in tumour cells has already been correlated with unfavourable prognosis in 40 BC patients [10] . High levels of TGF-b1 measured by enzymelinked immunosorbent assay in breast tumour cytosols were correlated with shorter DFS in BC patients [11] . In the last original article Annals of Oncology report, the TGF-b1 measured in tumour cytosols probably included tumour stromal cells expressing the protein; therefore, it is possible that TGF-b1 is overestimated in these samples.
A negative association between TGF-bRII and ER protein status was determined and corroborates previous experimental data [20] . In the present study, positive correlation between TGF-b1 and PgR at transcriptional and protein levels was observed. Positive [19] , negative [9] and the absence [21] of a correlation between TGF-b1 and PgR have been reported in BC.
A highly significant positive correlation between TGF-bRII and HER2 expression was detected at both transcriptional and protein levels. In addition, in HER2-negative cases, the positive expression of TGF-bRII in tumour cells was associated with good prognosis parameters (lower risk of metastasis development and death due to cancer). To the best of our knowledge, it is the first report addressing the association of TGF-b1 and TGF-bRII and HER2 expression in human breast tumour tissues.
Interestingly, increased DFS and OS in TGF-bRII-positive patients were detected in triple-negative patients. Cumulative evidence has shown the highly proliferative nature of these tumours, explaining the early recurrence and the worse outcome [22] . Despite of the low number of triple-negative patients evaluated, these results indicate that TGF-bRII expression can discriminate a subgroup of these patients with worse outcome. In HER2-positive group, an inversion of survival curves was observed. TGF-bRII-positive tumours showed decreased DFS and OS in comparison with negative tumours, although it was not statistically significant. Experimental data have shown the cooperation between the HER2-and TGF-b-signalling pathways to enhance motility and metastatic capabilities in BC cells [6, 23, 24] . Moreover, the anti-HER2 antibody trastuzumab blocked the promigratory effect of TGF-b1 on HER2-overexpressing mammary epithelial cells [23] . Taken together, these results indicate that loss of TGF-b growth-inhibitory effects in breast cancer can be at least in part explained by the down-regulation of TGF-bRII expression in tumour cells. The loss of TGF-bRII expression may play a role in tumour progression and metastasis, principally in HER2-negative patients (including those with triple-negative phenotype). Experimental models have shown that early loss of TGF-b1 and TGF-bRII resulted in more rapid primary tumour formation and increased metastasis [25, 26] . On the basis of the findings presented here, we can speculate that in the absence of HER2 amplification, TGF-b1 mediated by TGF-bRII binding acts as a tumour suppressor and can control tumour invasiveness by the aforementioned mechanisms. However, in the context of HER2 amplification, the tumour suppressor function of TGF-b1 cannot be assumed and might even be abrogated. The present data indicated that HER2 status could discriminate the prognostic role of TGFbRII in DFS and OS in BC patients.
In contrast with our findings, Buck et al. [20] did not detect down-expression of TGF-bRII protein in breast tumours compared with the adjacent breast tissues and reported that patients with TGF-bRII-positive tumours had significantly short OS (P = 0.037, n = 246). The authors also showed an association between TGF-bRII-positive expression and reduced OS in ER-negative patients (n = 87, P = 0.0083). In this study, HER2 status was not evaluated. Differences in the distribution of breast cancer subtypes, treatment response and survival have been reported in different populations [27] and could in part explain the conflicting results.
In conclusion, our data indicate that TGF-b1 and TGF-bRII protein expression in tumour cells could be considered as prognostic markers in breast cancer. Furthermore, these results are particularly relevant for TGF-b antagonists-based therapeutic strategies since they might ultimately produce undesired results, particularly in HER2-negative patients. 
